Scientus Pharma gets investment from Aphria

Scientus Pharma gets investment from Aphria

Aphria (TSX:APH; OTCQB:APHQF) has invested $11.5-million in Scientus Pharma’s HydRx Farms unit by way of a 2-year secured debenture convertible into common shares of Scientus Pharma at a rate of $2.75 a share.

Read More

Microbix posts 23% jump in Q3 revenue

Microbix posts 23% jump in Q3 revenue

Microbix Biosystems (TSX:MBX) reported record revenue for the fiscal third quarter ended June 30, 2017 of $2.8-million, up 23% from the same quarter a year ago. Net profit was $188,646, compared with $47,953 a year earlier.

Read More

Retinal KOL highlights benefits of Clearside treatment

Retinal KOL highlights benefits of Clearside treatment

At a KOL luncheon event held last week, leading retinal specialist, Dr. David Brown, outlined the shortcomings of current treatments for macular edema and discussed where Clearside Biomedical’s (NASDAQ:CLSD) suprachoroidal space delivery of steroid could prove beneficial.

Read More

HCW starts Alphatec at buy

HCW starts Alphatec at buy

H.C. Wainwright initiated coverage of Alphatec Holdings (NASDAQ:ATEC) with a “buy” rating and $4 price target, calling the company a “turnaround story in a high growth market.” The stock closed at $1.68 on August 11.

Read More

Ladenburg up Novavax to buy

Ladenburg up Novavax to buy

Ladenburg Thalmann upgraded Novavax (NASDAQ:NVAX) to “buy” from “neutral” with a new price target of $1.60 after the company presented encouraging preclinical data from its nanoparticle influenza vaccine, NanoFlu, and outlined a clinical development strategy targeting older adults. The stock closed at 97 cents on Aug. 8.

Read More

Microbix in $25-million viral antigen supply pact

Microbix in $25-million viral antigen supply pact

Microbix Biosystems (TSX:MBX) agreed to supply an existing long-term customer with an increasing quantity of its viral antigen products over the next five years, with an option to extend that term.

Read More

Clearside completes Phase 3 enrollment in uveitis

Clearside completes Phase 3 enrollment in uveitis

Clearside Biomedical (NASDAQ:CLSD) completed patient enrollment in the Phase 3 PEACHTREE clinical trial, which is designed to evaluate the safety and efficacy of CLS-TA for suprachoroidal administration for the treatment of macular edema associated with non-infectious uveitis.

Read More

Canaccord ups STAAR price target to $11

Canaccord ups STAAR price target to $11

Canaccord Genuity raised its price target for STAAR Surgical (NASDAQ:STAA) to $11 from $9 following the company’s second quarter results. The stock closed at $10.55 on August 2.

Read More

FDA completes inspection of ibalizumab plant

FDA completes inspection of ibalizumab plant

Theratechnologies (TSX:TH) has been notified by its partner, TaiMed Biologics of Taiwan, that the FDA has completed the pre-license inspection of the WuXi Biologics facility, where Theratechnologies’ ibalizumab will be manufactured.

Read More

Roth starts Apollo at buy

Roth starts Apollo at buy

Roth Capital Partners initiated coverage of Apollo Endosurgery (NASDAQ:APEN) with a “buy” rating and target price of $10. The stock closed at $6.21 on August 2.

Read More

Mackie cuts Intellipharmaceutics to sell

Mackie cuts Intellipharmaceutics to sell

Mackie Research Capital downgraded Intellipharmaceutics International (NASDAQ, TSX:IPCI) to “sell” from “speculative buy” and slashed its price target to $1 from $6 after a FDA advisory committee voted 22-1 against recommending approval of Rexista. The stock slumped $1.13 to close at $1.36 on July 27.

Read More